278 related articles for article (PubMed ID: 27352309)
1. Teneligliptin, a Chemotype Prolyl-Thiazolidine-Based Novel Dipeptidyl Peptidase-4 Inhibitor with Insulin Sensitizing Properties.
Kutoh E; Wada A; Terayama S
Clin Drug Investig; 2016 Oct; 36(10):809-18. PubMed ID: 27352309
[TBL] [Abstract][Full Text] [Related]
2. A ProspectIve, OpeN-Label, Randomized Study Comparing EffIcacy and Safety of Teneligliptin VErsus Sitagliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: INSITES Study.
Mohan V; Ramu M; Poongothai S; Kasthuri S
J Assoc Physicians India; 2019 Oct; 67(10):14-19. PubMed ID: 31571445
[TBL] [Abstract][Full Text] [Related]
3. Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.
Kim Y; Kang ES; Jang HC; Kim DJ; Oh T; Kim ES; Kim NH; Choi KM; Kim SR; You J; Kim SJ; Lee MK
Diabetes Obes Metab; 2019 Mar; 21(3):631-639. PubMed ID: 30362280
[TBL] [Abstract][Full Text] [Related]
4. Alogliptin: a DPP-4 inhibitor modulating adipose tissue insulin resistance and atherogenic lipid.
Kutoh E; Kuto AN; Akiyama M; Ozawa E; Kurihara R
Eur J Clin Pharmacol; 2023 Jul; 79(7):947-959. PubMed ID: 37193913
[TBL] [Abstract][Full Text] [Related]
5. REGULATION OF FREE FATTY ACID BY SITAGLIPTIN MONOTHERAPY IN DRUG-NAÏVE SUBJECTS WITH TYPE 2 DIABETES.
Kutoh E; Wada A; Hayashi J
Endocr Pract; 2018 Dec; 24(12):1063-1072. PubMed ID: 30289315
[TBL] [Abstract][Full Text] [Related]
6. Sitagliptin as an Initial Therapy and Differential Regulations of Metabolic Parameters Depending on its Glycemic Response in Subjects with Type 2 Diabetes.
Kutoh E; Kuto AN; Wada A; Hayashi J; Kurihara R
Drug Res (Stuttg); 2021 Mar; 71(3):157-165. PubMed ID: 33241550
[TBL] [Abstract][Full Text] [Related]
7. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
[TBL] [Abstract][Full Text] [Related]
8. Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes.
Ito R; Fukui T; Hayashi T; Osamura A; Ohara M; Hara N; Higuchi A; Yamamoto T; Hirano T
Drugs R D; 2015 Sep; 15(3):245-51. PubMed ID: 26224337
[TBL] [Abstract][Full Text] [Related]
9. Distinct glucose-lowering properties in good responders treated with sitagliptin and alogliptin.
Kutoh E; Hirate M; Wada A
Int J Clin Pract; 2015 Nov; 69(11):1296-302. PubMed ID: 26194442
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Effects of Teneligliptin and Sitagliptin, Two Dipeptidyl Peptidase 4 Inhibitors with Different Half-Lives, on Glucose Fluctuation and Glucagon-Like Peptide-1 in Type 2 Diabetes Mellitus.
Kurozumi A; Okada Y; Sugai K; Torimoto K; Tanaka Y
J UOEH; 2018; 40(1):1-9. PubMed ID: 29553070
[TBL] [Abstract][Full Text] [Related]
11. Comparison of teneligliptin and other gliptin-based regimens in addressing insulin resistance and glycemic control in type 2 diabetic patients: a cross-sectional study.
Singh H; Rohilla R; Jaswal S; Singla M
Expert Rev Endocrinol Metab; 2024; 19(1):81-87. PubMed ID: 38078453
[TBL] [Abstract][Full Text] [Related]
12. DPP-4 Inhibitor Teneligliptin Improves Insulin Resistance and Serum Lipid Profile in Japanese Patients with Type 2 Diabetes.
Kusunoki M; Sato D; Nakamura T; Oshida Y; Tsutsui H; Natsume Y; Tsutsumi K; Miyata T
Drug Res (Stuttg); 2015 Oct; 65(10):532-4. PubMed ID: 25368904
[TBL] [Abstract][Full Text] [Related]
13. Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients.
Kadowaki T; Haneda M; Ito H; Sasaki K; Hiraide S; Matsukawa M; Ueno M
Adv Ther; 2018 Jun; 35(6):817-831. PubMed ID: 29777520
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial.
Hong S; Park CY; Han KA; Chung CH; Ku BJ; Jang HC; Ahn CW; Lee MK; Moon MK; Son HS; Lee CB; Cho YW; Park SW
Diabetes Obes Metab; 2016 May; 18(5):528-32. PubMed ID: 26749529
[TBL] [Abstract][Full Text] [Related]
15. Effect of switching to teneligliptin from other dipeptidyl peptidase-4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease.
Kitada M; Ogura Y; Nitta K; Fujii M; Kanasaki K; Konishi K; Iida Y; Nakagawa A; Koya D
J Diabetes Investig; 2019 May; 10(3):706-713. PubMed ID: 30136384
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
Kadowaki T; Kondo K
Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan.
Kadowaki T; Haneda M; Ito H; Sasaki K; Yamada Y
Adv Ther; 2020 May; 37(5):2477-2492. PubMed ID: 32323194
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial.
Kim MK; Rhee EJ; Han KA; Woo AC; Lee MK; Ku BJ; Chung CH; Kim KA; Lee HW; Park IB; Park JY; Chul Jang HC; Park KS; Jang WI; Cha BY
Diabetes Obes Metab; 2015 Mar; 17(3):309-12. PubMed ID: 25475929
[TBL] [Abstract][Full Text] [Related]
19. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
Fukuda-Tsuru S; Anabuki J; Abe Y; Yoshida K; Ishii S
Eur J Pharmacol; 2012 Dec; 696(1-3):194-202. PubMed ID: 23022337
[TBL] [Abstract][Full Text] [Related]
20. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.
Tanaka S; Suzuki K; Aoki C; Niitani M; Kato K; Tomotsune T; Aso Y
Diabetes Technol Ther; 2014 Dec; 16(12):840-5. PubMed ID: 25144424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
